Discovery of Potent, Orally Bioavailable, Selective 5-HT_1A/B/D Receptor Antagonists

Discovery of Potent, Orally Bioavailable, Selective 5-HT_1A/B/D Receptor Antagonists Discovery of the First Potent, Selective 5-Hydroxytryptamine_1D Receptor Antagonist High-Efficacy 5-HT_1A Agonists for Antidepressant Treatment:  A Renewed Opportunity Dimers of 5HT 1 ligands preferentially bind to 5HT1b1d receptor subtypes Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold Development of selective agents targeting serotonin 5HT_1A receptors with subnanomolar activities based on a coumarin core The Selective 5-HT_1BReceptor Inverse Agonist 1‘-Methyl-5-[[2‘-methyl-4‘- (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4‘-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT_1Aand Serotonin Transporter Affinity within a Class ofN-Aryloxyethylindolylalkylamines The Extracellular Entrance Provides Selectivity to Serotonin 5-HT₇Receptor Antagonists with Antidepressant-like Behavior in Vivo